Siirry pääsisältöön
Käyttämääsi selainta ei enää tueta – lue lisää.
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
Ylin-
Alin-
Vaihto-
2025 Q4 -tulosraportti

Vain PDF

31 päivää sitten

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
55--
3 950--
50--
10 000--
9 000--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 34 min sitten
    34 min sitten
    Ok ok, lets send some Rockets to celebrate the good news ♥️🚀🚀🚀🚀🚀 Good night everyone.
  • 2 t sitten
    ·
    2 t sitten
    ·
    I feel my belief in retiring my parents just gets stronger and stronger now.
  • 2 t sitten
    ·
    2 t sitten
    ·
    Since we are a cheering squad, I think it must be acceptable to present one of the professionals who was there's assessment of Circios' presentation:
    2 t sitten
    ·
    2 t sitten
    ·
    I attended many other interesting presentations, but my favorite session was the last one of the conference, "New insights into AAV genome biology," which included a presentation that impressed me the most. This was a presentation from Erik Digman Wiklund from Circio Holding ASA, who presented a new vector that enables powerful circular RNA expression that increases AAV transgene production to such an extent that the dose of viral vectors can be significantly reduced, leading to much lower chances of severe immune response. The session also included a very interesting presentation from Mark Brimble, who showed that host cell DNA encapsulation is not a random process, but rather a skewed, AAV Rep-driven phenomenon.
  • 2 t sitten
    ·
    2 t sitten
    ·
    🧬 POSSIBLE HISTORIC BREAKTHROUGH AWAITS 🧬 Our man, Wiklund, has presented comprehensive circVec-data at ASGCT in Boston – the world's most important conference in gene and cell therapy. Most importantly: - up to 40x higher gene expression in the heart - up to 50x in the eye - potential for lower doses, better safety, and cheaper treatments Today's AAV gene therapy struggles with high doses and side effects. If circVec can indeed significantly reduce the dosage requirement, it could solve one of the biggest problems in the entire field. It could therefore be an important and historic breakthrough! Circio also states that the technology is generating strong interest among potential partners, and we can look forward to Monday! This is not just “another biotech news item”. This could be the start of something much bigger 🚂 (PS: Make your own choices. Don't use money you can't afford to lose. Do your own research.)
  • 2 t sitten · Muokattu
    ·
    2 t sitten · Muokattu
    ·
    Generally rock solid. Remember this is a professional conference. It's not just big pharma that's there. The world's foremost researchers in the field are there. What is delivered and presented must have very high scientific solidity, otherwise one is easily exposed. They have delivered professionally top-notch. It is absolutely crucial for being able to commercialize the technology platform in the next round. The strategy at ASGCT has strictly focused on the gene therapy project. They will extract the commercial opportunities here first. CNS is obviously held back. It is only contractual ties with Big Pharma that are the reason for this. Noted that "muscle tissue" was again listed as "ongoing". It has been completely silent about this for almost 1 year, then it was brought up. CircVec obviously has a general application in all organ and tissue types. It is unique. It is possibly the main message to the world's biotech industry and science. No quick or easy news. Rock-solid quality. That's the only thing that works in the long run. 2 news items are apparently coming in this q2 as I read the presentation. T-cell data and disease construct in the heart. Circio's international standing has been significantly strengthened. It is incredibly important. Trigger is coming. And partners are coming unless the entire technology gets "eaten". As a listed company with dispersed ownership, the company is vulnerable and an easy target.
    2 t sitten
    ·
    2 t sitten
    ·
    Professionals who were impressed:
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Vain PDF

31 päivää sitten

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 34 min sitten
    34 min sitten
    Ok ok, lets send some Rockets to celebrate the good news ♥️🚀🚀🚀🚀🚀 Good night everyone.
  • 2 t sitten
    ·
    2 t sitten
    ·
    I feel my belief in retiring my parents just gets stronger and stronger now.
  • 2 t sitten
    ·
    2 t sitten
    ·
    Since we are a cheering squad, I think it must be acceptable to present one of the professionals who was there's assessment of Circios' presentation:
    2 t sitten
    ·
    2 t sitten
    ·
    I attended many other interesting presentations, but my favorite session was the last one of the conference, "New insights into AAV genome biology," which included a presentation that impressed me the most. This was a presentation from Erik Digman Wiklund from Circio Holding ASA, who presented a new vector that enables powerful circular RNA expression that increases AAV transgene production to such an extent that the dose of viral vectors can be significantly reduced, leading to much lower chances of severe immune response. The session also included a very interesting presentation from Mark Brimble, who showed that host cell DNA encapsulation is not a random process, but rather a skewed, AAV Rep-driven phenomenon.
  • 2 t sitten
    ·
    2 t sitten
    ·
    🧬 POSSIBLE HISTORIC BREAKTHROUGH AWAITS 🧬 Our man, Wiklund, has presented comprehensive circVec-data at ASGCT in Boston – the world's most important conference in gene and cell therapy. Most importantly: - up to 40x higher gene expression in the heart - up to 50x in the eye - potential for lower doses, better safety, and cheaper treatments Today's AAV gene therapy struggles with high doses and side effects. If circVec can indeed significantly reduce the dosage requirement, it could solve one of the biggest problems in the entire field. It could therefore be an important and historic breakthrough! Circio also states that the technology is generating strong interest among potential partners, and we can look forward to Monday! This is not just “another biotech news item”. This could be the start of something much bigger 🚂 (PS: Make your own choices. Don't use money you can't afford to lose. Do your own research.)
  • 2 t sitten · Muokattu
    ·
    2 t sitten · Muokattu
    ·
    Generally rock solid. Remember this is a professional conference. It's not just big pharma that's there. The world's foremost researchers in the field are there. What is delivered and presented must have very high scientific solidity, otherwise one is easily exposed. They have delivered professionally top-notch. It is absolutely crucial for being able to commercialize the technology platform in the next round. The strategy at ASGCT has strictly focused on the gene therapy project. They will extract the commercial opportunities here first. CNS is obviously held back. It is only contractual ties with Big Pharma that are the reason for this. Noted that "muscle tissue" was again listed as "ongoing". It has been completely silent about this for almost 1 year, then it was brought up. CircVec obviously has a general application in all organ and tissue types. It is unique. It is possibly the main message to the world's biotech industry and science. No quick or easy news. Rock-solid quality. That's the only thing that works in the long run. 2 news items are apparently coming in this q2 as I read the presentation. T-cell data and disease construct in the heart. Circio's international standing has been significantly strengthened. It is incredibly important. Trigger is coming. And partners are coming unless the entire technology gets "eaten". As a listed company with dispersed ownership, the company is vulnerable and an easy target.
    2 t sitten
    ·
    2 t sitten
    ·
    Professionals who were impressed:
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
55--
3 950--
50--
10 000--
9 000--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

2025 Q4 -tulosraportti

Vain PDF

31 päivää sitten

Uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Yhtiötapahtumat

Datan lähde: FactSet, Quartr
Seuraava tapahtuma
2026 Q2 -tulosraportti
31.8.
Menneet tapahtumat
2025 Q4 -tulosraportti
15.4.
2025 Q2 -tulosraportti
28.8.2025
2024 Q4 -tulosraportti
10.4.2025
2024 Q2 -tulosraportti
29.8.2024
2023 Q4 -tulosraportti
25.4.2024

Tuotteita joiden kohde-etuutena tämä arvopaperi

Foorumi

Liity keskusteluun Nordnet Socialissa
Kirjaudu
  • 34 min sitten
    34 min sitten
    Ok ok, lets send some Rockets to celebrate the good news ♥️🚀🚀🚀🚀🚀 Good night everyone.
  • 2 t sitten
    ·
    2 t sitten
    ·
    I feel my belief in retiring my parents just gets stronger and stronger now.
  • 2 t sitten
    ·
    2 t sitten
    ·
    Since we are a cheering squad, I think it must be acceptable to present one of the professionals who was there's assessment of Circios' presentation:
    2 t sitten
    ·
    2 t sitten
    ·
    I attended many other interesting presentations, but my favorite session was the last one of the conference, "New insights into AAV genome biology," which included a presentation that impressed me the most. This was a presentation from Erik Digman Wiklund from Circio Holding ASA, who presented a new vector that enables powerful circular RNA expression that increases AAV transgene production to such an extent that the dose of viral vectors can be significantly reduced, leading to much lower chances of severe immune response. The session also included a very interesting presentation from Mark Brimble, who showed that host cell DNA encapsulation is not a random process, but rather a skewed, AAV Rep-driven phenomenon.
  • 2 t sitten
    ·
    2 t sitten
    ·
    🧬 POSSIBLE HISTORIC BREAKTHROUGH AWAITS 🧬 Our man, Wiklund, has presented comprehensive circVec-data at ASGCT in Boston – the world's most important conference in gene and cell therapy. Most importantly: - up to 40x higher gene expression in the heart - up to 50x in the eye - potential for lower doses, better safety, and cheaper treatments Today's AAV gene therapy struggles with high doses and side effects. If circVec can indeed significantly reduce the dosage requirement, it could solve one of the biggest problems in the entire field. It could therefore be an important and historic breakthrough! Circio also states that the technology is generating strong interest among potential partners, and we can look forward to Monday! This is not just “another biotech news item”. This could be the start of something much bigger 🚂 (PS: Make your own choices. Don't use money you can't afford to lose. Do your own research.)
  • 2 t sitten · Muokattu
    ·
    2 t sitten · Muokattu
    ·
    Generally rock solid. Remember this is a professional conference. It's not just big pharma that's there. The world's foremost researchers in the field are there. What is delivered and presented must have very high scientific solidity, otherwise one is easily exposed. They have delivered professionally top-notch. It is absolutely crucial for being able to commercialize the technology platform in the next round. The strategy at ASGCT has strictly focused on the gene therapy project. They will extract the commercial opportunities here first. CNS is obviously held back. It is only contractual ties with Big Pharma that are the reason for this. Noted that "muscle tissue" was again listed as "ongoing". It has been completely silent about this for almost 1 year, then it was brought up. CircVec obviously has a general application in all organ and tissue types. It is unique. It is possibly the main message to the world's biotech industry and science. No quick or easy news. Rock-solid quality. That's the only thing that works in the long run. 2 news items are apparently coming in this q2 as I read the presentation. T-cell data and disease construct in the heart. Circio's international standing has been significantly strengthened. It is incredibly important. Trigger is coming. And partners are coming unless the entire technology gets "eaten". As a listed company with dispersed ownership, the company is vulnerable and an easy target.
    2 t sitten
    ·
    2 t sitten
    ·
    Professionals who were impressed:
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, ​​eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Tarjoustasot

NorwayOslo Børs
Määrä
Osto
-
Myynti
Määrä
-

Viimeisimmät kaupat

AikaHintaMääräOstajaMyyjä
55--
3 950--
50--
10 000--
9 000--

Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt